
Sohn Conference: Accelerating Translation of Pediatric Cancer Research
Monday, February 26, 2018 - Wednesday, February 28, 2018
The Royal Society, 6-9 Carlton House Terrace, London, United Kingdom
This event is not organized or endorsed by The Royal Society
Pediatric cancer is the leading cause of death by disease past infancy among children in the United States and Europe. Despite prevailing increases in overall survival rates, it continues to be one of the most challenging diseases to treat. Our basic understanding of pediatric cancer biology has improved, but high rates of relapse remain; and 20% of pediatric cancer patients do not respond to therapy, ultimately dying from their disease. We now understand that childhood cancers are genetically distinct from their adult counterparts, and that current treatments developed for adults are particularly harsh on growing children, causing severe side effects. Thus, there is a critical need to refine established therapeutic approaches for this vulnerable population to improve treatment for patients around the world.
This 2.5-day international conference will advance the dialogue from the first meeting presented jointly by the Sohn Conference Foundation and the New York Academy of Sciences in 2016, the Sohn Conference: Pediatric Cancer in a Post-genomic World. Leading researchers, clinicians, pediatric cancer advocates, and industry and governmental stakeholders from around the globe will reconvene, this time in London, England, to discuss strategies to help bridge the gap between basic research discoveries and treatments for pediatric and adolescent cancer patients. The aim will be to provide a platform for these leaders from different countries and continents to share promising new findings, identify best practices, and develop a unified approach. Conference speakers will present emerging basic and clinical cutting edge research in pediatric cancers on topics including somatic and germline alterations, genomics and epigenomics, opportunities and challenges in immunotherapy, developmental biology, biology of tumor progression and relapse, technologies for non-invasive disease monitoring, biological determinants of survival, and challenges in clinical trial design and drug development.
Registration includes a complimentary, one-year membership to the New York Academy of Sciences. Complimentary memberships are provided to non-members only and cannot be used to renew or extend existing or expiring memberships. A welcome email will be sent upon registration which will include your membership credentials.
Registration
The Sohn Conference Foundation supports innovative initiatives that promote its mission to treat and cure pediatric cancer. Toward this goal, the Foundation seeks to embolden elite scientists researching pediatric cancers to collaborate across institutions and, with this Conference, across nations, to further research toward cures. This Conference is also a meaningful reflection of the Foundation’s unique philanthropic model: the Foundation raises funds by convening leading investment professionals to share their best ideas and fundraise for the cause of pediatric cancer research. It is therefore the Foundation’s privilege to partner with the New York Academy of Sciences to convene the world’s scientific leaders who will change the course of treating pediatric cancer, ultimately, saving more children from cancer and treatment side-effects.
Monday
February 26, 2018
Registration
Introduction and Welcome Remarks
Speakers
Day 1 Keynote Address: Planes, Trains and Different-fields
Speaker
Session I: Inherited Predisposition to Childhood Cancers
Li-Fraumeni Syndrome: The Molecular Basis of Cancer Predisposition, Early Detection and Prevention
Speaker
Revealing the Identity of Cancer Cells
Speaker
Networking Coffee Break
Session II: Somatic Alterations in Pediatric Cancers: Genomics and Epigenomics
New Vulnerabilities in Pediatric Cancer
Speaker
Ewing Sarcoma: An Enhancer Disease with Widespread Epigenetic Heterogeneity
Speaker
Next-generation Diagnostics in Pediatric Neurooncology
Speaker
Closing Remarks
Day 1 Ends
Tuesday
February 27, 2018
Networking Breakfast, Poster Set Up
Session III: Opportunities and Challenges in Immunotherapy for the Treatment of Pediatric Cancers
Targeting Childhood Solid Cancers with Engineered T Cells
Speaker
Pediatric Cancer Immunotherapy: Not a Trickle Down from Medical Oncology
Speaker
The Role of Hypermutation and Replication Repair Deficiency in Response of Childhood Cancers to Immune Checkpoint Inhibitors
Speaker
Networking Coffee Break
Session IV: Incorporating Developmental Biology into Our Understanding of Pediatric Cancers
Targeting Neuroblastoma — Mouse Models to Therapeutics for ALK and MYCN
Speaker
Targeting Chromatin Complexes in Pediatric Cancer
Speaker
Networking Lunch and Poster Viewing
Session V: Hot Topic Talks from Submitted Abstracts
Tumor Mutational Burden Analysis of Pediatric Tumors Provides a Diagnostic Tool for Germline Predisposition and Reveals Novel Candidates for Immune Checkpoint Inhibition
Speaker
Targeting Metabolic Adaptation in MYCN Amplified Pediatric Neuroblastoma
Speaker
Session VI: Emerging Biology of Tumor Progression and Relapse
Stress-mediated Translational Control of Sarcoma Metastasis
Speaker
Approaches to Target Cancer Metabolism
Speaker
Heterogeneity through Space and Time Drive the Clinical Behavior of Childhood Brain Cancers
Speaker
Patient-driven Discovery in Pediatric Oncology
Speaker
Day 2 Closing Remarks
Networking Reception and Poster Session
Day 2 Ends
Wednesday
February 28, 2018
Networking Breakfast
Day 3 Keynote Address: Juvenile Myelomonocytic Leukemia: Learning from Patients in a World without Walls
Speaker
Networking Coffee Break
Session VII: Strategies and Challenges in Clinical Trial Design and Drug Development
Innovative Designs and Strategy to Accelerate Translation of Pediatric Cancer Research into New Effective Therapies
Speaker
Elucidating and Targeting Evolving Therapy Resistance in Neuroblastoma
Speaker
Innovative Clinical Trials and New Drug Development: A Pharmaceutical Industry Perspective
Speaker
Panel Discussion: Accelerating Drug Development
Speakers
Networking Lunch
Early Career Investigator and Underrepresented Minority Mentoring Lunch
Session VIII: Emerging Technologies in Non-invasive Disease Monitoring
Development of Liquid Biopsies/cfDNA in Osteosarcoma: An Unmet Need
Speaker
Clonal Evolution in Pediatric Solid High Risk Cancers Based on Sequential Analysis of Circulating Tumor DNA
Speaker
Imaging Tumor Cell Metabolism — From Mouse to Man
Speaker
Networking Coffee Break
Session IX: Hot Topic Talks from Submitted Abstracts
The Orally Bioavailable Small Molecule CDK2/9 Inhibitors CYC065 and CCT68127 Are Potent Inhibitors of MYCN via Transcriptional Repression
Speaker
Intellectual Outcome in Children with Sensorineural Hearing Loss Following Treatment for Malignant Embryonal Brain Tumors
Speaker
Session X: Biological Determinants of Late Effects in Pediatric Cancer Survivors
Mitigating the Risk of Treatment-related Complications in Childhood Cancer Survivors — Are We There Yet?
Speaker
Constitutional DNA Variants and Other Biomarkers Predictive of Late Effects in Childhood Cancer Survivors
Speaker